ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
EDTD
|
81 |
22K |
41 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
22K
|
41
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
EDTD
|
81 |
22K |
30 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
22K
|
30
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
79 |
21K |
8 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
79
|
21K
|
8
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
EDTD
|
81 |
22K |
59 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
81
|
22K
|
59
|
|
ASX - By Stock
|
LPD |
Re:
Managements Awkward Silence
|
|
EDTD
|
107 |
49K |
19 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
107
|
49K
|
19
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Nova Announces Pricing of US$3.3m NASDAQ IPO
|
|
EDTD
|
59 |
14K |
1 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
59
|
14K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
EDTD
|
391 |
80K |
13 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
80K
|
13
|
|
ASX - By Stock
|
LPD |
Re:
General Discussion
|
|
EDTD
|
1.1K |
391K |
12 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
1.1K
|
391K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
EDTD
|
130 |
36K |
49 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
36K
|
49
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
EDTD
|
130 |
36K |
29 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
36K
|
29
|
|
ASX - By Stock
|
LPD |
Re:
General Discussion
|
|
EDTD
|
1.1K |
391K |
10 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
1.1K
|
391K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
EDTD
|
130 |
36K |
12 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
130
|
36K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
EDTD
|
130 |
36K |
17 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
130
|
36K
|
17
|
|
ASX - By Stock
|
LPD |
Re:
Managements Awkward Silence
|
|
EDTD
|
107 |
49K |
11 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
107
|
49K
|
11
|
|
ASX - By Stock
|
LPD |
Re:
Managements Awkward Silence
|
|
EDTD
|
107 |
49K |
7 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
107
|
49K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
EDTD
|
80 |
25K |
7 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
80
|
25K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
EDTD
|
80 |
25K |
12 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
80
|
25K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
EDTD
|
10K |
3.2M |
7 |
25/06/24 |
25/06/24 |
ASX - By Stock
|
10K
|
3.2M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
EDTD
|
10K |
3.2M |
4 |
25/06/24 |
25/06/24 |
ASX - By Stock
|
10K
|
3.2M
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
EDTD
|
905 |
266K |
11 |
23/06/24 |
23/06/24 |
ASX - By Stock
|
905
|
266K
|
11
|
|
ASX - By Stock
|
LPD |
Re:
General Discussion
|
|
EDTD
|
1.1K |
391K |
25 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
1.1K
|
391K
|
25
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
EDTD
|
80 |
25K |
18 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
80
|
25K
|
18
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
EDTD
|
21K |
7.6M |
18 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
21K
|
7.6M
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Offer Results
|
|
EDTD
|
35 |
12K |
24 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
35
|
12K
|
24
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
EDTD
|
596 |
212K |
6 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
596
|
212K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
EDTD
|
596 |
212K |
10 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
596
|
212K
|
10
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
EDTD
|
21K |
7.6M |
27 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
21K
|
7.6M
|
27
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
EDTD
|
5.7K |
2.8M |
4 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
5.7K
|
2.8M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
EDTD
|
5.7K |
2.8M |
2 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
5.7K
|
2.8M
|
2
|
|
ASX - By Stock
|
RAC Biotech |
Re:
Dr Tillett - The Accidental Biotech CEO
|
|
EDTD
|
7 |
3.2K |
23 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
7
|
3.2K
|
23
|
|
ASX - By Stock
|
RAC Biotech |
Re:
Dr Tillett - The Accidental Biotech CEO
|
|
EDTD
|
7 |
3.2K |
18 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
7
|
3.2K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RAC Investor Presentation May 2024
|
|
EDTD
|
55 |
16K |
15 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
55
|
16K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene
|
|
EDTD
|
234 |
64K |
18 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
234
|
64K
|
18
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
6 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
65
|
25K
|
6
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
12 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
65
|
25K
|
12
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
13 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
65
|
25K
|
13
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
9 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
65
|
25K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
EDTD
|
905 |
266K |
2 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
905
|
266K
|
2
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
25 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
65
|
25K
|
25
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
46 |
17K |
29 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
46
|
17K
|
29
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Extension to Entitlement Offer Closing Date
|
|
EDTD
|
70 |
25K |
6 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
70
|
25K
|
6
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Directors & Key Managements Intention with Rights Offer
|
|
EDTD
|
57 |
19K |
18 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
57
|
19K
|
18
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Renounceable Entitlements Offer to Fund Arrangement of Phase
|
|
EDTD
|
96 |
41K |
24 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
96
|
41K
|
24
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
EDTD
|
1.0K |
304K |
25 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
304K
|
25
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
EDTD
|
905 |
266K |
18 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
905
|
266K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
EDTD
|
905 |
266K |
20 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
905
|
266K
|
20
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
EDTD
|
1.0K |
304K |
8 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
1.0K
|
304K
|
8
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
426 |
130K |
12 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
426
|
130K
|
12
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
426 |
130K |
9 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
426
|
130K
|
9
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
426 |
130K |
31 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
426
|
130K
|
31
|
|